Clinical and Biological Effects of Recombinant Interferon-β Administered Intravenously Daily in Phase I Trial
- 1 June 1988
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon Research
- Vol. 8 (3), 357-366
- https://doi.org/10.1089/jir.1988.8.357
Abstract
Interferon-β serine (IFN-βser) was administered intravenously (i.v.) daily for 14 days at doses of 3, 10, 30 x 106 units to 19 patients. In this Phase I trial, IFN-γser was tolerated without limiting fever or subjective toxicities. At 30 x 106 units, 3 patients developed hematologic toxicity and dose escalation was thus terminated. No patient developed detectable binding or neutralizing antibody to IFN-β. A significant (p < 0.006) increase in serum β2-microglobulin and a significant ( < 0.005) increase in 2′, 5′-oligoadenylate synthetase (2-5A) in peripheral mononuclear cells were identified. Increase in these proteins did not correlate with dose or with the disappearance of serum IFN over the first 5 h after injection. Two patients, one with renal carcinoma and one with melanoma, had objective responses. This trial further confirms safety and biological potency of this synthetic mutant of IFN-β.Keywords
This publication has 5 references indexed in Scilit:
- Plasma lipoprotein changes in humans induced by β-interferonAtherosclerosis, 1987
- Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiationCell, 1986
- Interferon regulates c-myc gene expression in Daudi cells at the post-transcriptional level.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Site-specific mutagenesis of the human fibroblast interferon gene.Proceedings of the National Academy of Sciences of the United States of America, 1984
- Purification and molecular characterization of human fibroblast interferonArchives of Biochemistry and Biophysics, 1981